These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2825 related articles for article (PubMed ID: 7703717)

  • 21. Identification of a VIP-specific receptor in guinea pig tenia coli.
    Teng BQ; Grider JR; Murthy KS
    Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G718-25. PubMed ID: 11518684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts.
    Robberecht P; Waelbroeck M; De Neef P; Tastenoy M; Gourlet P; Cogniaux J; Christophe J
    FEBS Lett; 1988 Feb; 228(2):351-5. PubMed ID: 2830146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
    Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional expression of VIP receptors in normal, immortalized and transformed mammary epithelial cells.
    Berthon P; Mirossay L; Ito S; Calvo F; Gespach C
    Life Sci; 1992; 50(11):791-8. PubMed ID: 1311049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The stimulatory effects and binding characteristics of PACAP27 in rat dispersed pancreatic acini.
    Kashimura J; Shimosegawa T; Iguchi K; Mochizuki T; Yanaihara N; Koizumi M; Toyota T
    Tohoku J Exp Med; 1993 Nov; 171(3):243-54. PubMed ID: 7512757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the immunomodulatory properties of the secretin-glucagon family of peptides on mouse lymphoid cell functions and the demonstration of specific receptors on T cells.
    Nguyen TT; Krco CJ; Gores A; Go VL
    Immunol Invest; 1987 Nov; 16(7):555-77. PubMed ID: 2832322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of functional receptors for vasoactive intestinal peptide (VIP) in rat peritoneal macrophages.
    Segura JJ; Guerrero JM; Goberna R; Calvo JR
    Regul Pept; 1991 Apr; 33(2):133-43. PubMed ID: 1652777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of functional VIP/PACAP receptors in the human erythroleukemic HEL cell line.
    Lema-Kisoka R; Hayez N; Langer I; Robberecht P; Sariban E; Delporte C
    Peptides; 2001 Dec; 22(12):2155-62. PubMed ID: 11786204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic AMP formation in chicken brain: effect of vasoactive intestinal peptide, peptide histidine-isoleucine (PHI), and some PHI-related peptides.
    Dejda A; Matczak I; Wiktorowska-Owczarek A; Nowak JZ
    Pol J Pharmacol; 2003; 55(5):747-51. PubMed ID: 14704471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP-inducing hormones in the human gastric cancer cell line HGT-1. Homologous desensitization of VIP receptor activity.
    Gespach C; Emami S; Rosselin G
    Biochem Biophys Res Commun; 1984 Apr; 120(2):641-9. PubMed ID: 6329177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
    Gespach C; Bawab W; de Cremoux P; Calvo F
    Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of vasoactive intestinal peptide receptors in human liver.
    Rodríguez-Henche N; Rodríguez-Pena MS; Guijarro LG; Prieto JC
    Biochim Biophys Acta; 1994 Mar; 1221(2):193-8. PubMed ID: 8148398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PACAP and VIP stimulate enzyme secretion in rat pancreatic acini via interaction with VIP/PACAP-2 receptors: additive augmentation of CCK/carbachol-induced enzyme release.
    Schmidt WE; Seebeck J; Höcker M; Schwarzhoff R; Schäfer H; Fornefeld H; Morys-Wortmann C; Fölsch UR; Creutzfeldt W
    Pancreas; 1993 Jul; 8(4):476-87. PubMed ID: 8103217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
    Moretti C; Bagnato A; Solan N; Frajese G; Catt KJ
    Endocrinology; 1990 Nov; 127(5):2117-26. PubMed ID: 2171907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homologous regulation of vasoactive intestinal peptide (VIP) receptors on rat peritoneal macrophages.
    Pozo D; Guerrero JM; Calvo JR
    Peptides; 1995; 16(2):313-8. PubMed ID: 7784261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
    Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
    Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
    Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
    Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
    Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 142.